{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:59:24Z","timestamp":1761519564243,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.3816\/ccc.2011.n.006","type":"journal-article","created":{"date-parts":[[2012,11,9]],"date-time":"2012-11-09T12:22:19Z","timestamp":1352463739000},"page":"42-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Tolerability of Biweekly Bevacizumab, Irinotecan, Folinic Acid and Fluorouracil Intravenous Bolus (BIFF Regimen) in Patients With Metastatic Colorectal Cancer: The Southern Italy Cooperative Oncology Group Experience"],"prefix":"10.3816","volume":"10","author":[{"given":"Pasquale","family":"Comella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Massidda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Natale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Putzu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sandomenico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Filippelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Palmeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Condemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Vessia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Barberis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Ionta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2011.n.006_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other disease","volume":"407","author":"Carmeliet","year":"2000","journal-title":"Nature"},{"key":"10.3816\/CCC.2011.n.006_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2011.n.006_bib3","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/0008-5472.CAN-04-0074","article-title":"Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors","volume":"64","author":"Tong","year":"2004","journal-title":"Cancer Res"},{"key":"10.3816\/CCC.2011.n.006_bib4","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs tumor response to radiation","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"key":"10.3816\/CCC.2011.n.006_bib5","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/sj.bjc.6601005","article-title":"Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11","volume":"88","author":"Wildiers","year":"2003","journal-title":"Br J Cancer"},{"issue":"suppl 1","key":"10.3816\/CCC.2011.n.006_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.9-suppl_1-11","article-title":"Targeted therapy of colorectal cancer: Clinical experience with bevacizumab","volume":"9","author":"Fernando","year":"2004","journal-title":"Oncologist"},{"key":"10.3816\/CCC.2011.n.006_bib7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2011.n.006_bib8","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2011.n.006_bib9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.2007.15.5390","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results From the BICC-C Study","volume":"26","author":"Fuchs","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2011.n.006_bib10","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2011.n.006_bib11","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/annonc\/mdf133","article-title":"Addition of either irinotecan or methotrexate to bolus fluorouracil and high-dose leucovorin every two weeks in advanced colorectal carcinoma: A randomized study of the Southern Italy Cooperative Oncology Group","volume":"13","author":"Comella","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2011.n.006_bib12","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/annonc\/mdi185","volume":"16","author":"Comella","year":"2005","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2011.n.006_bib13","first-page":"203","article-title":"Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: Pooled analysis of two consecutive Southern Italy Cooperative Oncology Group trials","volume":"5","author":"Comella","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"10.3816\/CCC.2011.n.006_bib14","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/sj.bjc.6601214","article-title":"Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma","volume":"89","author":"Comella","year":"2003","journal-title":"Br J Cancer"},{"key":"10.3816\/CCC.2011.n.006_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CCC.2011.n.006_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.3816\/CCC.2011.n.006_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.3816\/CCC.2011.n.006_bib18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00384-009-0655-9","article-title":"A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer","volume":"24","author":"Cao","year":"2009","journal-title":"Int J Colorectal Dis"},{"key":"10.3816\/CCC.2011.n.006_bib19","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdp533","article-title":"The Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review","volume":"21","author":"Welch","year":"2010","journal-title":"Ann Oncol"},{"key":"10.3816\/CCC.2011.n.006_bib20","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","article-title":"Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody","volume":"93","author":"Yuan","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3816\/CCC.2011.n.006_bib21","first-page":"1205","article-title":"Clinical pharmacokinetics of oxaliplatin: A critical review","volume":"6","author":"Graham","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CCC.2011.n.006_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000229787","article-title":"Phase IV Study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer","volume":"77","author":"Sobrero","year":"2009","journal-title":"Oncology"},{"key":"10.3816\/CCC.2011.n.006_bib23","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","article-title":"Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE)","volume":"26","author":"Grothey","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2011.n.006_bib24","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1200\/JCO.2008.17.4540","article-title":"Bevacizumab beyond progression: Does this make sense?","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811700627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811700627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:56:46Z","timestamp":1761519406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811700627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S1533002811700627"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2011.n.006","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Tolerability of Biweekly Bevacizumab, Irinotecan, Folinic Acid and Fluorouracil Intravenous Bolus (BIFF Regimen) in Patients With Metastatic Colorectal Cancer: The Southern Italy Cooperative Oncology Group Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2011.n.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}